Tax breaks aim to boost R&D investment

Published: 2003-08-08 07:00:00

Updated: 2003-08-08 07:00:00

The temporal adoption of an alternative minimum tax rate will spur smaller pharmaceutical firms to spend more R&D investment, the Korea Pharmaceutical Manufacturers Association said recently.

This series of stimulus measures came after the KPMA called for the National Assembly to enact a new l...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK